Professor Focuses on Treating Opioid Use Disorder

Deborah Mash, Ph.D., is a professor of neurology at the Dr. Karin C. Patel College of Allopathic Medicine. She is also the Chief Executive Officer and founder of DemeRx a clinical-stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder.

DemeRx has partnered with ATAI Life Sciences — a global biotech platform with a special focus on psychedelic medicine — to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and ATAI submitted Clinical Trial Applications for a Phase II study in opioid-dependent patients. This joint venture will also develop screening procedures, dosing guidelines, and best practices for opioid withdrawal management to ensure patient safety.

Last year, Mash was invited to speak at the 2021 Wonderland: Miami about her research. Wonderland: Miami brings together an impressive group of global psychedelic medicine leaders, including scientists and researchers, investors, entrepreneurs, therapists and patients, government. This year’s event will be Nov. 14-16 at the Mana Lynwood Convention Center. The topic is Healing, Science, Art, Experience, Culture, Music, Investing, History, Technology, Business, and the Future.

Posted 02/27/22